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1. Introduction 
Modern pharmaceutical therapy increasingly demands the development of 
pharmaceutical products with controlled drug release and prolonged drug effect. The 
slow drug liberation from the product ensures better absorption and a steady drug 
level in the body, hereby the drug's therapeutical effect will be uniform. 
The slow drug release has further advantages in certain cases. For example, 
iron(H) sulfate, one of the most commonly applied pharmacons in the therapy of 
anaemia, effects gastric mucosa irritation, which can be decreased remarkably by the 
slow liberation of iron. Another advantage of retard products is that they make one 
daily dose possible, and thus better patient compliance results. 
The production of medicines with prolonged drug release is achievable with 
pharmaceutical technological methods. Pharmacists working in the field of 
pharmaceutical technology have expressed a definite need for new, simple, time- and 
cost-saving methods and also for new substances with suitable parameters for direct 
processing. 
The so-called melt technologies are in the centre of interest again partly 
because of the new substances and methods, and partly because they usually make 
quick and simple manufacturing possible within a short time and at low costs. 
Another advantage is that they are environment-friendly and can be used for 
manufacturing solid products with controlled drug release. 
Spherical crystallization, which ensures the production of basic material with 
appropriate parameters and properties, is also a field on which great interest is 
focussed nowadays. With the spherical crystallization process crystals with a round 
shape can be produced, and they make it possible to apply surface treatment (e.g. 
crystal coating) immediately or to perform direct tablet compression. The preliminary 
granulation of the substance is not necessary, which also contributes to its time- and 
cost-saving character. The powder rheological properties of round crystals are better, 
they can be filled into the capsules easily, thus giving the final product. 
References to the author's own articles are made with bold numbers. 
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2. Aims 
The aim of my PhD work was to produce solid dosage forms from iron(II) 
sulfate with the use of new pharmaceutical technological methods. The industrial 
processing of iron(II) sulfate and the production of solid dosage forms (tablets, 
capsules) with conventional methods are difficult, lengthy and expensive. Therefore 
new, time- and cost-saving methods are needed in iron processing, with special regard 
to slow and prolonged drug release from the product. 
In my research work the following objectives were set: 
=> The overview of the literature related to the subject; 
=> The selection of the appropriates iron(II) sulfate hydrate form for melt technology 
with thermostability tests; 
=> The study of crystallization from melt and from solution, and the processing of 
iron(II) sulfate using the melt solidification technology and the spherical 
crystallization process; 
=> The investigation of the applicability and reproducibility of the above-mentioned 
technologies, the classification of the produced samples from aspects of 
pharmaceutical technology and biopharmacy. 
3. Literature 
3.1 Physiology of iron 
Iron is an essential component for crucial cellular processes. It is necessary in 
the oxygen-transport as a component of haemoglobin and of enzymes in the 
respiration. Iron containing proteins are involved in the production of ATP and DNA-
synthesis and other physiological processes [1,2]. It is also essential for the regulation 
of cell growth and differentiation, e.g. in the central nervous system and in the growth 
of the brain. Consequently, the actual iron status influences the normal human 
physiology and the state of health [3]. 
An adult body contains approximately 3-5 g of iron and it needs on the 
average 1 mg iron per day. Healthy adults absorb about 10% to 15% of dietary iron 
[4], but individual absorption is influenced by several factors. In certain ages (infancy, 
/ 
adolescence) and states (menstruating- and pregnant women) iron requirements are 
high [5, 6]. Iron absorbs mainly from the upper part of the small intestine [7]. Iron 
absorption is minimal from the stomach, but at acidic pH iron-ions dissolve and are 
reduced (Fe3+-> Fe2+). The new researches confirm that ferro (Fe2+) ions are absorbed 
quickly and in a great quantity by passive diffusion [8, 9], and ferri (Fe3+) ions assist 
in the physiological process of absorption and pass into the blood by active transport 
by means of mucosa-transferrin. Iron absorption is influenced decisively by the iron 
stores. The absorption increases when body stores are low and when iron stores are 
high, absorption decreases [7,10-12]. If the iron intake is low and not enough to cover 
the requirement, a negative iron balance evolves. This negative balance results in iron 
deficiency and iron deficiency anaemia with typical symptoms [13-15]. 
3.2 Replacement of iron, iron therapy 
In iron deficiency and anaemia it is necessary to take in iron. Among the 
medicines one can find iron containing tablets, capsules, syrups, effervescent tablets 
and injections [16,17], In the daily therapy usually iron salt containing medicines are 
administered orally. In cases of anaemia, tablets are generally used twice or three 
times a day (for a period of months) to fill up the iron stores [2]. The patients' 
compliance improves if only one medicine dose is necessary daily. 
The typical side effects of iron therapy are gastrointestinal effects (e.g. nausea, 
diarrhoea or constipation, lack of appetite, epigastric ache, sometimes 
oversensitiveness), and the most common is gastric irritation as a result of the iron 
reaching the stomach suddenly in a high concentration [10, 16]. In modem therapy 
tablets with sustained release are preferred as they increase patient compliance and 
decrease the side effects. 
Several iron salts are suitable for iron replacement (e.g. ferrous succinate, 
ferrous lactate, ferrous fumerate, ferrous glycine sulfate, ferrous glutamate, ferrous 
gluconate, ferrous citrate, iron(III) hydroxide etc.). The absorption of iron compounds 
is correlated with iron(II) sulphate, as it is a standard, its absorption is regarded as the 
100% level [10]. At present several medicines available on the market contain iron(II) 
sulfate as their active agent. 
3.3 Characteristics of iron(II) sulfate 
It is difficult to work up iron(II) sulfate as a dosage form. The problems 
involved in the preparative technologies are the following: 
3 
=> Oxidation 
Iron is oxidized easily (Fe2+-> Fe3+), which is provoked by humidity and heat. 
Upon the effect of oxidation the quantity of iron(II) and iron(III) ions changes in 
the preparation, which in turn influences the applicability, the effect and the safety 
of medicine. 
Corrosion 
One of the processing problems is that iron causes the attrition and corrosion of 
the machines within a short time. This is an extra cost of the production. 
=> Gastric irritation 
Gastric irritation can decrease considerably if the iron release from the product is 
slow with a uniform rate. 
Iron(II) sulfate resides in crystal forms with 1-7 molecules of water. The water 
solubility of different hydrate forms is different and it varies with temperature (Fig. 
1.). 
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Fig. 1. The dissolution curve of iron(II) sulfate in water [18] 
The iron(II) sulfate crystals soluted in water crystallize as heptahydrate from 
solution under adequate circumstances (e.g. temperature, saturation of solution etc.) 
[19-21]. 
By means of the crystallization of iron from the solution with the conventional 
crystallization process, the product's crystal form will ideally be cubic. Cubic crystals 
are shaped like cubes or boxes, the axis lengths and the axis angles are uniform {a = b 
= c, a = P = y = 90°). One of the atoms is located in the centre of the unit cell and the 
others are located at equal distances from it (body-centered cubic (bccj crystal system) 
(Fig 2.) [22]. Moreover, iron(II) sulfate monoclinic crystals are also described in 
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literature. In the case of monoclinic crystals 
the three axes are unequal in length, two of 
them are at right angles, while the third is at 
an angle other than 90° (a a = ¡3 -
90° and y * 90°) [21, 23-27], In the 
literature the axis lengths are as follows: 
a : b : c = 1 .1828:1:1 .5427 [18, 28-30], 
while the iron(II) sulfate heptahydrate 
available on the market is heterodisperse, 
with variable crystal shapes and sizes. 1 Fig. 2. The structure of a regular bee-crystal 
© 
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3.4 In general about crystallization 
Crystallization is one of the oldest and most important processes, used in the 
food, pharmaceutical and chemical industries. It is used principally for purification 
and separation. Depending on the starting material, the crystallization process can 
take place from solution and from melt, but it is difficult to separate the two areas 
technically. 
3.4.1 Crystallization from melts 
3.4.1.1 Conventional crystallization from melts 
Nowadays melt crystallization is used mainly in the preparation of raw 
materials [31], but it can also be applied in pharmaceutical technology. It is used for 
separation and purification [32-34] based on the various melting points of 
components. It is well applicable in the production of organic substances with high 
purity, for isomer separation, seawater desalination etc. [35]. From the energetical 
aspect melt crystallization is more advantageous than other separation techniques 
because it takes place at a lower temperature, so the phase transition enthalpy is 
lower, which is also favourable for heat-sensitive materials [36]. 
Classically melt crystallization means the melting of a material or material 
mixture and its solidification upon the effect of cooling. Only those materials can be 
crystallized from the melt which can be melted without decomposition and can be 
heated above the melting temperature in a melted state [37], We can distinguish solid 
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layer and suspension melt crystallization [38]. Solid layer crystallization is based on 
the formation of a crystal layer on a cooled surface, and solid-liquid separation is also 
realized during the process. In suspension crystallization the solid product is present 
as crystals, which are freely suspended in the melt. Supersaturation is generated by 
the cooling of the melt. Both the layer- and suspension-based processes can be carried 
out with continuous or fractional, and static or dynamic procedure [39]. 
The kinetics of melt crystallization is simpler than the kinetics of 
crystallization from solution. The phase of nucleation and phase of crystal growth can 
be distinguished in the process of crystallization. Temperature transport plays an 
important role in the process, and there is primary heterogeneous nucleation indicated 
by an artificial centre [36]. In the melt suspension crystals can grow freely, but in the 
layer the surface and the neighbouring crystals limit the crystal growth. Hence it is 
better to use the term layer growth instead of crystal growth [40]. 
3.4.1.2 Melt technologies 
Several melt technologies are used such as melt-granulation [41], melt-
extrusion [42-45], technologies based on dropping or spraying of the melt [46, 47]. 
These are applied in pharmaceutics to give shape, to increase the solubility or 
bioavailability, to modify the release of the active agent or to work up materials which 
cannot be processed by traditional methods. It is also applicable to prepare products 
with sustained drug release [48, 49]. In these cases usually the auxiliary material is 
melted and not the drug. In the melt technology auxiliary materials such as 
polyethylene-glycols [50, 51], waxes [52, 53], stearine [54], fats, fatty acids, fatty 
alcohols, glycerides [55, 56] and glycerine derivatives [57] can be used. In these cases 
the mechanism of drug release from the products is erosion and diffusion [58,59]. 
A new and modern method in the field of pharmaceutical technology is the 
melt solidification technique from drop (special hot melt technology). It is a melt 
crystallization technology, which means the solidification from melt in drop form 
[60]. It is used mostly for the purpose of giving shape, and it is well applicable in the 
preparation of raw materials with varied shape and in great quantities if the uniform 
shape, surface and size are basic requirements [61-63]. The chemical industrial 
machine and the different feeders are shown in Figure 3. and Figure 4. 
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Fig. 3. The principle of operation (a) and the industrial machine (b) for the melt solidification 
in drop [64] 
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3.4.1.3 Determination of surface free energy for the melt solidification technology 
The product shape is influenced by the surface free energy of the cooling 
surface in the melt solidification technology. The surface free energy can be 
calculated from the contact angles between the surface and test liquids [66-70]. 
Contact angles can be determined with Drop Shape Analysers [71]. There are many 
different theories for the calculation of the surface free energy on the basis of contact 
angles with such an analyser [72-77]. 
The theory of Owens and Wendt is based on the different wetting properties of 
the liquid on different surfaces (Fig.5.). On the other hand, the contact angles of 
different liquids on the same surface are different. 
water on glass water on teflon water on steel 
Fig. 5. Contact angles of water on different surfaces 
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This is the wetting phenomenon, which can be explained by the interaction 
between interfaces, by the surface free energy, and it is also influenced by adsorption 
and the liquid properties [78-80, 81]. The most important parameter of wetting is the 
contact angle ( 0 = theta) (Fig. 6.). 
Fig. 6. Contact angle ( 0 ) between 
solid surface and liquid 
where: ySv = interfacial tension between solid surface and vapour, ySL = interfacial tension between 
solid surface and liquid, yLV= interfacial tension between liquid and vapour 
The thermodynamics of the contact angle is described by the Young equation 
(1805) [82], The behaviour of the liquid drop is determined by the interfacial tensions 
arising among the three interfaces ( j or o), and according to the Young equation 
equilibrium arises when the vector sum of the surface forces is zero. 
COS0 — Y sv Y S! 
r, The Young equation 
Theoretical relationships by Owens et al. [74] 
The interfacial tension of a liquid (yi) results from the polar (yip) and disperse 
(yid) component of interfacial tension (1). The same applies to the interfacial tension 
of a solid phase (ys) (2). 
YRVW* Y=YS+YPS < D , < 2 ) 
The interfacial tension between the solid surface and the liquid drop can be calculated 
with (3), (4): 
YSI = YS + YI-2UYS-Y,+V/YI (3) 
c o s 0 = / | y , y , ^ , y I (4) 
If the contact angles and the yip and yid (from data base) of test fluids are known, x-y 
pairs can be composed according to the above equations (5), (6): 
\YRY, 
d -i d 
Y, \Y, 
l+cos e y, 
= X = y (5), (6) 
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It leads to the y = mx + b line equation, and from this the surface free energy can be 
calculated (7), (8): 
rt 7 j 
YÍ = m and Ys 
u 
d p 
rs=rs+r, 
(7) 
(8) 
3.4.2 Crystallization from solution 
The crystallization from solution takes place in the supersaturated solutions 
[83, 84], Supersaturation can be achieved both in physical and chemical ways, e.g. 
heating or cooling of the solution or the salting-out method. It is very important to 
know the solubility diagram of the material (Fig. 7.). The main characteristics of this 
diagram are the metastable and the instable zones. In the instable zone the 
spontaneous formation of crystal nucleus occurs, while the growth of the crystals is 
observable in the metastable zone. The crystallization process can be governed in this 
zone and it can usually be determined experimentally [85, 86]. 
supersaturated 
instable 
supersaturated 
metastable zone 
supersaturation curve 
saturation curve 
(saturated stable) 
unsaturated 
stable Fig. 7. Solubility diagram 
Temperature 
Nucleation and crystal growth are the two important phases of crystallization. The 
diagram of nucleation is presented in Figure 8. 
I <B 0 § 
! 
/ 
AGS 
(surface) 
1 ¿Gent rcrit \ 
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\ \ 
\ \ 
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\ \ V \ \ 
Fig. 8. The diagram of nucleation 
Size of nucleus, r 
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The nucleation rate (J) is influenced by the change of the surface free energy of the 
particle (AG) [87] and it can be expressed by: 
J = exp (-AG/kT) 
where 
J = nucleation rate, AG = free energy between a small particle of solid solute and the 
solute in solution, k = rate constant, T = temperature. 
The particle size belonging to the maximum level of the AG curve is the 
critical particle size, where either crystal formation is started or the particle will be 
resoluble [88]. 
The phase of crystal growth means the formation of a regular lattice from 
molecules. The rate of crystal growth can be described by: 
R = (1/AjMdW/dt) = lie-Ac8 
where 
R= overall growth rate based on mass deposition, Af= total crystal surface area, W= 
mass of crystals, t= time, ko= growth rate constant, Ac^ concentration of crystal [89]. 
With adequate parameters (e.g. cooling rate, rotation speed of mixer, solvent, 
seed crystal etc.) it is possible to change the morphological properties and the crystal 
habit during the crystallization process from solution, hereby spherical crystals can 
also be produced with this method. This is the so-called non-typical spherical 
crystallization process. The alteration of the morphological properties results in better 
flowability and compressibility, and it also makes the materials suitable for direct 
compression. If the traditional crystallization processes are not suitable for the 
preparation of spherical agglomerates, the typical spherical crystallization process 
can also be used. This technique was defined first by Kawashima [89]. The typical 
spherical crystallization process employs three solvents: one is the substance 
dissolution medium, another is the medium which partially dissolves the substance 
and the third is the wetting solvent for the substance [90]. In the three-solvent system 
the dissolved drug material is carried in emulsion drops. Later the drops become 
oversaturated with respect to the drug material and in situ seed formation starts 
followed by crystal formation. Therefore the emulsion drop-size determines the size 
of crystal agglomerates. Many drugs have been successfully transformed into 
spherical agglomerates with this technology [91-97]. 
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3.5 Prolonged drug effect, the pharmaceutical-technological possibilities of 
prolongation 
From the conventional peroral dosage forms the active agent is liberated 
quickly, through absorption the plasma drug level increases continuously and, having 
reached the maximum concentration (Cmax), it decreases until complete elimination. In 
conventional therapy repeated administration is necessary to maintain the required 
drug concentration in blood [98]. If the dose size and the frequency of administration 
are chosen correctly, the therapeutic "steady state" levels of drug can be achieved and 
maintained. However, there are a number of potential limitations associated with 
repetitive administration of conventional dosage forms [99,100], 
Nowadays pharmaceutical technological researches tend to develop dosage 
forms with sustained release [101, 102]. These sustained release preparations are 
designed to release the drug contained therein at a continuous and more controlled 
rate for a longer period of time [103-105]. Consequently, peroral administration of a 
"single dose" of a sustained release product increases the duration of therapeutic 
action and the therapeutic effect of the drug contained therein beyond the level 
achieved normally with a single dose of the corresponding non-sustained conventional 
counterpart. 
The in vivo effect of a drug is mostly demonstrated by the plasma-
concentration-time curve [98]. The parameters calculated from the curve (ka, ke, Ws, 
t'/j eiinb AUC, W , Cmax, MAT, MRT, BHabs, BHrei) characterize the drug effect [106]. 
The most important kinetic parameter for a sustained release preparation is the 
liberation at a constant rate, which ensures the constant plasma drug level in a longer 
period of time [107]. This is called zero order kinetics [49, 51]. According to zero 
order kinetics, the rate of release is constant and independent of the amount of the 
maintenance dose remaining in the dosage form. Ideally, the preparation consists of 
two portions, the first provides the initial dose which releases rapidly, and the second 
is the maintenance or sustained dose with slow drug liberation [100]. 
There are several formulation methods for achieving sustained drug release. 
Applicable technologies include classical coating, embedding of drug in a wax, fat or 
plastic material, microencapsulation, chemical binding to ion-exchange resins and 
incorporation in an osmotic pump [49, 51, 108, 109]. These processes can be used in 
combination as well. 
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4. Materials and methods 
4.1 Materials 
Iron(II) sulfate monohydrate (Ph. Eur. 3., Merck Eurolab GmbH, Darmstadt, 
Germany) was used as the active agent for the production of solid particles with 
special hot melt technology. The particle size was 44-104 pm. The auxiliary materials 
(bed materials) were white wax (Cera alba, melting range: 62-66 °C, Ph. Hg. VII., 
Hungaropharma, Budapest, Hungary,), stearin (Stearinum, melting range: 54-67 °C, 
Ph. Hg. VII., Hungaropharma, Budapest, Hungary) which is a mixture of stearic acid 
and palmitic acid, Compritol ATO 888® (glyceryl behenate, Ph. Eur. 3., Gattefosse, 
France, melting range: 69-74 °C) and Precirol ATO 5® (glyceryl palmitostearate, Ph. 
Eur. 3., Gattefosse, France, melting range: 53-57 °C). 
The basic material in spherical crystallization was iron(II) sulfate heptahydrate 
available on the market (Ph. Hg. VII., Hungaropharma, Budapest, Hungary) with 10 
pm - 2 mm particle size. Stearin (Stearinum, Ph. Hg. VII., Hungaropharma, Budapest, 
Hungary) was used as the coating material during the coating process. 
4.2 Methods 
4.2.1 Preformulation studies 
4.2.1.1 Reactions kinetic investigations 
The aim of the reactions kinetic investigations was to select the iron-
compound that is applicable in melt technology. Samples of iron(II) sulfate 
monohydrate and heptahydrate were stored in a furnace at 120 and 160 °C for 2 hours. 
Samples were taken after 0.5,1 and 2 hours. The iron(II)-concentration of the samples 
was measured by an analytical method based on a colour reaction. Fe2+-ions and 2,2'-
bipyridil compose a red and water-soluble complex which can quantitatively be 
measured spectrophotometrically at 522 nm [110-112] and the activation energy can 
be calculated [113-115]. The activation energy is the amount of energy required for a 
reaction, the difference in energy between the initial state and activated state. 
4.2.1.2 Thermostability test 
The thermostability test was carried out in accordance with the guidelines of 
ICH-International Conference on Harmonization, signed as Q1A [116]. The changing 
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of the Fe content was measured in time by means of the already mentioned colour 
reaction. The Fe3+content of the samples was calculated in such a way that the 
actually measured Fe2+content was subtracted from the total iron content. 
4.2.2 Product development 
4.2.2.1 The method of melt solidification in drops (special hot melt technology) 
Preformulation studies for the special hot melt technology 
The surface free energies of different cooling surfaces (enamel, steel and 
teflon surfaces) were measured. 3 test fluids such as distilled water, diiodomethane 
and glycerine were used for all the measurements, with known polar and disperse 
parts of their interfacial tensions. The contact angles were measured for all the surface 
materials with a Krtiss Drop Shape Analyser (DSA, G10, Kriiss, Hamburg) and their 
surface free energies were calculated according to the theory of Owens et al. [74]. 
3 parallel examinations were carried out in each case. 
The contact angle of a solid particle can be measured with the Drop Shape 
Analyser. The contact angle of an ideal spherical particle is 180°. Solid particles were 
produced with the special hot melt technology at different temperatures. The contact 
angles of the produced particles were measured. The melt of stearine and steel surface 
were used in the course of the investigations. 
Product development with special hot melt technology 
The essence of this method is the drop forming of the melted material with 
laboratory equipment and the solidification of drops on the cooling surface at a 
definite surface temperature [38, 117, 118]. After the determination of the process 
parameters (temperature, the material of cooling surface, drop-size etc.), particles with 
various shapes can be produced with this method [64]. 
The method of melt solidification is a special hot melt technology, 
practically a modified dropping process. The advantage of this technology is that 
shape formation (spherical particles) and drug release regulation are realized in one 
production step [119]. The other advantage is that it is a solvent-free, consequently an 
environment-friendly process. The laboratory equipment developed by Btilau and 
Ulrich was used for the production [117]. The most important parts of this equipment 
are the heated pipette and the pastillation cell with cooled surface (Fig. 9.). 
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Healed pipette 
Fig. 9. Special laboratory equipment for melt solidification [117] 
The process parameters such as the temperature of the melt, the temperature 
and the material of the cooled surface, the size of the drops and the distance between 
the pipette and the cooled surface could be varied. After the determination of process 
parameters in preformulation studies, the production of spherical solid particles is fast 
and simple [120]. The geometrical properties of the particles are influenced by the 
material and the surface free energy of the cooling surface as well as by the 
temperature of the surface and the melt. 
The process of this melt solidification technology is the following: iron(II) sulfate is 
suspended and homogenized in the molten bed materials. This suspension is dense 
with high viscosity and is prepared in a double-walled glass connected to a 
thermostate. This suspension is mixed at 50 rpm. The preheated melt (suspension) is 
dropped onto a cooled surface at adequate temperatures by means of a heated pipette 
(pipette diameter: 1.2 mm). The dropping height of the melt is 6 mm. After dropping 
the suspension solidifies without any deformation effect of cooling, thus the 
procedure results in round solid particles (Fig. 10.). 
melted auxiliary material (bed material) 
^ — = 3 = active agent 
mixture of melted bed material and active agent 
I 
dropping 
^ — = = solidification 
spherical particle 
Fig. 10. The scheme of the special hot 
melt technology 
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4.2.2.2 Spherical crystallization 
Preformulation studies for spherical crystallization 
The aim of the preformulation studies was to examine the effect of the 
crystallization process parameters on the produced samples with a view to produce 
iron(II) sulfate heptahydrate spherical crystals. We used the non typical spherical 
crystallization process from solution. A SCHMIZO duplicate reactor crystallizer with 
0.5 1 volume was used equipped with a mixer, the mixing speed of which could be 
regulated. The crystallization process can be realized according to different cooling 
programs with a thermostat connected to the set. The concentration of the saturated 
solution was constant (135 g FeSCW H2O/IOO g water). During the preformulation 
studies the starting temperature, the cooling rate, the cooling mode, the speed of the 
mixer and the solvent were varied. The necessity of the seeding crystal was also 
studied. The samples were produced at laboratory scale. 
Melt-coating of spherical crystals 
The scale-up process of the lab-sample the parameters of which were optimal 
on the basis of preformulation study was performed, and 100.0 g of the iron(II) sulfate 
heptahydrate crystals (Fe/12) with a diameter of 0.5-1 mm was coated. This was 
carried out in a rotating steel pan, with stearin used as the coating material. The 
carrier liquid of the melted stearin was 95% alcohol. An air spray technique was used 
for the atomisation of the liquid. The process parameters were as follows: nozzle 
diameter: 0.8 mm, atomisation air pressure 0.1 bar, flow rate of coating liquid: 5 
ml/min, coating liquid temperature: 60 °C, drying air temperature: 20 ± 2 °C and pan 
rotation speed: 25 rpm. 
4.2.3 Measuring methods 
• Stereo microscopic study 
The habits of the particles were studied with a Zeiss stereo microscope (Zeiss 
KL 1500 LCD, Jena, Germany). 
•Electron microscopic study 
The properties of the formulations (surface and cross-section) were observed 
by scanning electron microscopy (Hitachi 2400S Hitachi Scientific Instrument Ltd., 
Tokyo, Japan). A Polaron sputter coating apparatus (Polaron Equipment Ltd., 
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Greenhill, UK) was applied to induce electric conductivity on the surface of the 
sample. The air pressure was 1.3-13 mPa. 
•Particle size analysis 
The particle size analysis of samples produced with special hot melt 
technology was performed with a screwmicrometer (Mitutoyo, Tokyo, Japan). The 
mean diameter was calculated from the linear size of 100 particles, with accuracy to 
three decimals. 
The particle size of the particles produced by the crystallization process was 
measured by sieve analysis (DIN ISO 3310, Retsch GmbH & Co., Haan, Germany). 
•Determination of roundness 
To determine the roundness of the particles produced with the crystallization 
process, an image analyzer (Laborlux light microscope, Quantiment 500MC image 
analyzer - LEICA Cambridge Ltd., Anglia) was used. Its software makes it possible 
to measure the length and the diameter of the particles and also to calculate the 
roundness according to the following relationship [121]: 
roundness = perimeter2/4n*surface area* 1,064 
The value of 1.064 is the correction factor of the perimeter. If the roundness value is 
about 1, the investigated particle's shape is approximately round. 
•X-ray powder diffraction (XRPD) 
X-ray powder diffraction profiles were taken with an X-ray diffractometer 
(Philips PW 1050/70 PW 1710). The measurement conditions were as follows: 
radiation source: CuKa , scan speed: 0.035 (29), step size: 0.035 (20), time per step: 
1.0 s. 
• Thermoanalytical tests 
In order to observe the physical and chemical changes arising upon the effect 
of heating, thermoanalytical investigations (TG-, DTG-test) were performed with a 
MOM apparatus (MOM, Budapest, Hungary). The test parameters were the 
following: mean sample weight: 50 mg, heating rate: 5 °C/min. The studies were 
performed in air atmosphere. 
• Mass measurement 
This measurement was performed with an analytical balance (Sartorius H 110) 
with four-decimal accuracy. The mean particle mass was calculated after the 
measurement of 100 particles in accordance with the Ph. Hg. VII. 
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• Determination of the total iron content 
The total iron content of the investigated samples was determined by atomic 
absorption method. The samples were submitted to a burning process and the residue 
was dissolved in the mixture of diluted hydrochloric acid and sulphuric acid. The 
solution was diluted into the concentration range where it could be measured. 
Measurements were carried out with a Perkin Elmer 4100 atomic absorption 
spectrometer (Bodenseewerk Perkin Elmer GmbH, Überlingen, Germany) at 248.3 
nm in air-acetylene gas. The iron content of each particle is given with respect to 
iron(II) sulfate monohydrate. 
• Determination of iron(III)-content 
Fe2+ -ions form a colourful complex with 2,2'-bipyridil in an acidic medium, 
the colour intensity of which can be measured spectrophotometrically (Spectronic 
Unicam, Helios Alpha, Cambridge) at 522 nm. The Fe3+ content was determined by 
subtracting the actually measured Fe2+ content from the total iron content of the 
sample. 
•Measuring of flow time and bulk density 
The volume of 100 ml from each sample was investigated to determine flow 
time and bulk density (g/100 ml) with the ASTM-D (USA-standard) apparatus official 
in the Ph. Hg. VII. 6 parallel measurements were performed for each sample. 
•In vitro drug dissolution study 
Dissolution studies were performed with a Pharma Test PTW 2 apparatus 
(Pharma Test GmbH, Hainburg, Germany) paddle method, under sink conditions. The 
medium was 900 ml of artificial gastric fluid (pH = 1.2 ± 0.1) with a temperature of 
37 ± 0.5 °C. The rotation speed was 100 rpm. Samples of 5 ml were extracted at 
regular time intervals. The sample-times were 0.5, 1, 2, 3, 4, 5, 6 h and 0.5, 1, 2, 3 ,4 
h. The samples were analysed with a Perkin Elmer 4100 atomic absorption 
spectrometer (Bodenseewerk Perkin Elmer GmbH, Überlingen, Germany) under the 
following conditions: flame-atomizing, wavelength 248.3 nm, slit width 0.7 nm, air-
acetylene gas mixture (air: 0.8 L/min, acetylene: 3.5 L/min), and read time 5 s. 
• In vivo study 
New Zealand white rabbits (mean body weight 2632 ±155 g), 6 animals in 
each group, were treated orally with the particles (dosage: 20 mg iron(II) sulfate/kg). 
The particles were introduced directly into the stomach via a catheter and were 
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washed in with 30 ml of water. The control animals were treated with an equivalent 
dose of iron(II) sulfate in aqueous solution (0.5% w/v). Blood samples were collected 
from the marginal ear veins 12 or 14 times, at 0,0.5,1,1.5,2, 3,4, 5,6,7, 8 and 10 h, 
with two additional samples at 0.25 and 0.75 h for the aqueous solution. Heparin was 
used as anticoagulant. Samples were stored at 5 °C until analysis. 
Afterwards, the animals were anaesthetized with iv. pentobarbital, the mucous 
membranes of the stomach and ileum were examined and the macroscopic changes 
were evaluated. 
Animal investigations were carried out with the approval of the Ethical 
Committee for Animal Research, University of Szeged (registration number: 1-74-
7/2002). 
Evaluation of the active agent: 
Iron(II) concentrations in plasma samples were measured with the aid of a 
Ferrozin kit (Diagnostikum Rt, Budapest, Hungary). At pH = 4.8, Fe3+ dissociates 
from transferrin and is reduced to Fe2+ by the ascorbic acid incorporated in the kit. 
ri i 
This Fe forms a red complex with ferrozin. Its absorbance at 560 nm is directly 
proportional to the Fe2+ concentration. The test is linear up to a Fe2+ concentration of 
179 pmol/L. 
For the analysis, 200 pi of plasma or standard solution was used. The plasma 
Fe2+ concentrations were measured against a reagent blank. The physiological Fe2+ 
concentration was determined on blood samples taken at 0 h, just before the 
treatment. This value was subtracted from the Fe2+ concentrations measured after the 
treatment. 
Pharmacokinetic evaluation 
Computerized data processing was carried out with MEDUSA 1.8. Curves 
were fitted to the concentration values within each group and pharmacokinetic 
analysis was performed in accordance with the one-compartment open 
pharmacokinetic model. 
The plasma concentration curve was plotted and the main pharmacokinetic 
parameters were determined: the absorption half-life (ti/2abs), the elimination half-life 
(ti/2eiim), the mean residence time (MRT), the time to peak (tmax) and the peak 
concentration (Cmax). The area under the curve (AUC») needed for the estimation of 
the bioavailability was also calculated [122]. 
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• Statistical calculations 
The kinetic calculations (rate constant, correlation coefficient, slopes, 
intercepts) of the in vitro dissolution tests were performed with Excel, with a 
confidence level of 95%. The statistical evaluation of the kinetic parameters of the in 
vivo results was performed by SPSS ANOVA one-way statistical analysis. 
5. Results 
5.1 Result of thermostability assays 
The heat resistance of iron(II) sulfate monohydrate and heptahydrate available 
on the market was investigated because of the inclination of iron-compounds to 
oxidation. The aim of our research was to establish which iron hydrate form tolerates 
the heat better and is suitable for the special hot melt technology. In order to obtain 
the desired results, reaction kinetic and thermostability tests had to be performed 
[123], The samples were heated and the Fe2+ content decrease was detected. On the 
basis of this change, the order of reaction was defined and the activation energy was 
calculated with the Arrhenius-equation. The results of reaction kinetic tests are shown 
in the Table 1. 
Table 1. Results of reaction kinetic test 
Equation of decomposition Order of 
decomposition 
Activation 
energy 
Iron (II) sulfate 
heptahydrate 
120 °C:y = 323.3-e"UMjy5x 
R 2 = 0.997 
First order 21299.8 J/mol 160 °C:y = 301.28-e-™ x 
R 2 = 0.9895 
Iron (II) sulfate 
monohydrate 
120 °C:y = -5.7994x +326.94 
R 2 = 0.8983 
Zero order 4942.2 J/mol 160 °C: y = -6.668x + 326.63 
R 2= 0.9003 
The decomposition of the heptahydrate form can be described with an 
exponential equation, which means that decomposition is carried out according to first 
order kinetics, namely the rate of decomposition depend on the amount of the starting 
material. The decomposition of iron(II) sulfate monohydrate can be described with a 
linear equation, so this is a zero order kinetic reaction. The reaction rate is constant in 
time. 
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The difference between the values of the activation energies was significant. 
The activation energy of iron(II) sulfate heptahydrate is greater with one order, so the 
same increase in temperature results in oxidation happening at a considerably greater 
rate while iron(II) sulfate monohydrate can tolerate the increase of temperature to a 
greater extent. 
Therefore the thermostability test of iron(II) sulfate monohydrate was also 
performed according to the guidelines of ICH (Table 2.) Table 3. shows the 
parameters of investigation and the detected Fe3+ content of samples. 
Table 2. Parameters of the thermostability test according to ICH Q1A protocol 
Long term testing Accelerated 
testing 
Temperature (°C) 25 ± 2 40 ± 2 
Relative humidity (%) 60 ± 5 75 ± 5 
Time (month) 12 6 
Table 3. Parameters and results of the thermostability test 
Samples Container Temperature (°C) 
Relative 
humidity 
(%) 
Fe34 content of 
samples* 
(%) 
1 glass, opened 20-23 40-45 2.45 
2 plastic, guaranteed snap 20-23 40-45 1.78 
3 glass, opened 25 60 3.02 
4 plastic, guaranteed snap 25 60 2.50 
5 glass, opened 40 75 2.38 
6 plastic, guaranteed snap 40 75 1.84 
* at the end of the test 
The results show that iron(II) sulfate monohydrate is not oxidized to a great 
extent under the above-mentioned conditions. The greatest change in the Fe3+ content 
was about 3%. 
It can be established that oxidation is slow in iron(II) sulfate monohydrate 
stored at a high temperature, high relative humidity and for a long period of time. This 
confirms the results of the reaction kinetic test. 
The results of the investigations of reaction kinetics and thermostability 
revealed that the formulation of a solid dosage form of iron(II) sulfate hydrate forms 
can be realized in the way shown in Figure 11., and iron(II) sulfate monohydrate is 
suitable for the purpose of special hot melt technology. 
2 0 
Formation of spherical particles by crystallization 
Crysta l l i zat ion f r o m mel t Crysta l l i zat ion f r o m solut ion 
(Hot melt technology) 
1 I 
Melt solidification from drop 
(Special hot melt technology) 
I 
Iron(II) sulfate monohydrate 
Conventional, non typical 
spherical crystallization 
Iron(II) sulfate heptahydrate 
Fig. 11. Processing possibility of iron(II) hydrate forms (monohydrate and heptahydrate) 
5.2 Results 1-The results of investigations of samples developed by melt 
solidification technology 
Pre-formulation studies with an aim to prepare samples using the melt solidification 
technology 
In the melt solidification technology (special hot melt technology) an 
important parameter which influences the shape of the produced sample is the surface 
free energy of the cooling surface. The surface free energy determines the contact 
angle between the drop and the cooling plate and if the melt-drop keeps its drop shape 
or flows on the surface during the solidification time. Three different surfaces such as 
enamel, steel and teflon were tested and the surface free energies calculated [120, 
124] (Table 4.). 
Table 4. The surface free energies of the tested surfaces 
Surface 
material Line equation 
ysp (mN/m) 
Ys
d 
(mN/m) Surface free 
energy (mN/m) 
Enamel y = 4.958x +5.1569 24.58 26.63 51.21 
Steel y = 2.2003x + 4.9999 4.84 24.90 29.73 
Teflon y = 2.0393x + 3.8067 4.18 14.44 18.61 
Melt solidification technology requires a surface with moderate surface free 
energy. In the case of high surface free energy the melt drop may become deformed 
during solidification, and on a surface with low surface free energy the drop may flow 
before solidification as a round particle. Consequently, our choice fell on steel surface 
in processing iron with special hot melt technology. 
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The shape and structure of the resulting particles depend strongly on the 
temperature of the melt during drop formation and on the temperature of the 
solidification surface. We tested the effect of temperatures on the resulting particles in 
preformulation studies. First the melt of stearine with temperatures of 55, 60, 65, 70 
and 80 °C was dropped onto a steel surface, the temperature of which was constantly 
6 °C. In the second part the temperature of melted stearine was constant (60 °C) and 
the temperature of the cooled surface was varied (2, 6, 10, 20, 30 and 40 °C). The 
contact angle of the resulting solid particles was measured (Fig. 12-13.). 
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Fig. 12. Effect of the melt temperature on the contact angles of the particles using the melt of 
stearin (the surface temperature was constant at 6 °C) 
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Fig. 13. Effect of the surface temperature on the contact angles of the particles using the melt 
of stearin (the melt temperature was constant at 60 °C) 
The figures show that the contact angle of the melt increases with the decrease 
of the melt temperature. The effect of the melt temperature is more remarkable than 
the effect of the surface temperature. If the melt temperature is close to the 
solidification temperature, a sudden increase can be observed in the theta values. The 
shape of the product is then mostly spherical. Such a sudden change cannot be 
observed in the case of the surface temperature. The decrease in the surface 
temperature influences the contact angle only with a few degrees but it does not lead 
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to a considerable change in the shape of the product. Thus it can be established that 
during the special hot melt technology the melt temperature has a greater effect on 
product shape than the surface temperature where the melt solidifies. And if the melt 
temperature is near the solidification temperature, the solidification time can be 
decreased considerably and the occasional drop deformation can be prevented. 
Table 5. shows the results of the same investigation of other auxiliary materials (white 
wax, mixture of stearin and white wax, Compritol ATO 888 " and Precirol ATO 5®) 
and of stearin. The results are similar, namely the lower melt temperature of the tested 
auxiliary materials resulted in a particle with greater contact angle. After preliminary 
studies 5 samples were produced with special hot melt technology (Table 6). 
Table 5. Drop forming properties of auxiliary materials and the contact angles of produced 
samples as shape characteristics 
Stearin White wax 
Stearin and 
white wax 
(1:1) 
Compritol 
ATO 888® 
Precirol 
ATO 5® 
Melting range 
(°C) 54-67 62-66 69-74 53-57 
T|iiel|/Tsurface Contact angles of products (0/°) 
53.4/10.6 106.62 - - 158.24 
57.9/10.6 72.64 - 152.49 - 157.76 
62.4/10.6 72.24 145.34 142.81 - 158.64 
66.8/10.6 71.00 136.83 132.93 144.29 156.70 
71.4/10.6 - 99.50 126.28 139.27 -
76.0/10.6 54.26 99.64 114.28 144.12 158.96 
80.8/10.6 - 99.44 103.96 149.52 -
76.0/20.2 - - 158.06 -
80.8/20.2 - - 156.54 -
Table 6. The composition of samples and the process 
Product Auxiliary material 
Amount of 
auxiliary 
material 
(%) 
Amount of 
active 
agent 
(%) 
s^urface 
(°C) 
Tmelt 
(°C) 
Viscosity 
(Pa-s) " 
Sample 1 
Natural 
Stearin 50 50 10.6 57.9 0.401 ± 0.243 
Sample 2 White wax 50 50 10.6 66.8 0.384 ± 0.008 
Sample 3 Stearin-white wax 25-25 50 10.6 66.8 
0.850 
± 0.0258 
Sample 4 
Semisynthetic 
Compritol 
888 ATO® 50 50 20.2 76.0 
2.946 
± 1.673 
Sample 5 Precirol ATO 5® 50 50 10.6 62.4 
2.09 
± 0.842 
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Using the process parameters presented in Table 6., almost round particles can 
be produced and the contact angle of particles can be measured with the help of a 
Drop Shape Analyser. A picture of the produced particle made with a CCD camera 
connected to the DSA equipment can be seen in Figure 14. 
Fig. 14. Picture of solid particle produced by special 
hot melt technology,Sample 2, Theta: 174 + 0.1° 
5.2.1 Application of natural bed materials (stearine and white wax) in melt 
technology 
Pharmaceutical technological evaluation of samples 
For the development of the iron(II) sulfate-containing lipophilic matrices, we 
used a special hot-melt technology (melt solidification in drops) which provides solid 
spherical particles. Natural bed materials such as stearine and white wax were used. 
The pharmaceutical technological parameters of the samples 1-3 are shown in Table 
7. The mass and the size of samples are both uniform. The mean mass is around 10 
mg and the mean sample diameter is about 2 mm. The low values of the standard 
deviations confirm that the production of the samples is well reproducible. The cause 
of the similar parameters is the similar drop forming properties and viscosity of the 
melt of bed materials. 
The iron(II) sulfate monohydrate content of particles is between 6 and 7 mg. 
The low standard deviations demonstrate that sample production with this technology 
is reproducible with respect to homogeneous drug content. The iron present in the 
product is not oxidized considerably during the process. The Fe3+-content in the 
product is only 0.02-0.03 % higher than in the starting material. 
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Table 7. Pharmaceutical technological parameters of samples containing iron(II) sulfate 
monohydrate and natural bed materials, produced by special hot melt technology 
Sample 1 Sample 2 Sample 3 
Particle mass (nig) 10.6 ±0.001 
10.5 
±0.002 
10.9 
±0.002 
Particle size (mm) 1.792 
±0.051 
1.998 
±0.189 
1.776 
± 0.078 
Particle's total Fe(II)S04 content 
(mg) 
6.41 
±0.183 
6.97 
±0.483 
6.15 
± 0.074 
Particle's Fe3* content (%)* 
•starting Fe3+ content: 0.40% 
0.42 
±0.01 
0.43 
±0.01 
0.43 
±0.02 
In vitro drug release studies 
The in vitro release of iron (II) sulfate from the produced formulations was 
studied in different fluids, such as distilled water, artificial gastric fluid and phosphate 
buffer. The produced samples store iron in the solid state, incorporated in the 
lipophilic matrix. The iron(II) sulfate released from the matrices must be in the 
dissolved form in the stomach for effective absorption in the proximal intestine. Since 
the highest drug release was detected in the artificial gastric fluid with an acidic 
character, the in vitro release results for the artificial gastric fluid are shown (Fig. 15.). 
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Fig. 15. In vitro dissolution of iron(II) sulfate in artificial gastric fluid at 37 °C, from 
samples 1 (o), 2 (0) and 3 (A) 
The rates of dissolution of the iron(II) sulfate from the various lipophilic 
matrices were basically low. However, considerable differences were observed in the 
amount of active agent liberated. The greatest quantity of iron(II) sulfate was 
dissolved from sample 1, i. e. 70% of the total iron content. This was followed by 
sample 3, with 45% release, and then sample 2, from which 26% of the total drug 
content was liberated during the study. In the in vitro tests, no significant differences 
In SZEGED "is! 
\t/> 
2 5 u. 
in drug release were detected between sample 2 and sample 3, whereas there were 
significant differences between sample 1 and sample 2, and between sample 1 and 
sample 3. 
The in vitro test demonstrated that the rate of dissolution of the iron(II) sulfate 
was of approximately zero kinetic order with uniform release. The rate constants and 
the correlation coefficients (Table 8.) calculated in kinetic calculations confirm that 
the release of iron(II) sulfate was really zero order kinetic because there is no 
significant difference between the parameters of the two kinetic models, but the first 
order kinetic model in the case of sample 1 has a better correlation coefficient. 
Table 8. Kinetic parameters of samples (based on in vitro experiments) 
zero-order model first-order model 
rate constant 
(*) 
correlation 
coefficient 
(R) 
rate constant 
(*) 
correlation 
coefficient 
(R) 
Sample 1 -8.3007 0.9768 -0.0839 0.9978 
Sample 2 -3.4952 0.9843 -0.0220 0.9907 
Sample 3 -4.9306 0.9905 -0.0435 0.9983 
The drug release results in artificial gastric fluid are in accordance with the 
physico-chemical properties, and more particularly with the solubility properties of 
the iron(II) sulfate and the auxiliary materials. White wax and stearin are both 
insoluble in water and in acid medium, but stearin has an acid character and contains 
some water-soluble acid. Accordingly, the highest drug release was observed from 
sample 1, which contained stearin as bed material. The drug release was lower from 
sample 3, containing stearin and white wax, and the least from sample 2, which 
contained only white wax as bed material. The drug release profiles are in accordance 
with the surface of the samples, too. 
In vivo experiments 
A summary of the in vivo studies in rabbits is shown in Fig. 16. The curves 
demonstrate the increase in the plasma iron(II) concentration in comparison with the 
basic level measured before treatment. The points are the mean plasma iron(II) 
concentrations with the standard deviation in each group of 6 animals. As concerns 
the basic plasma iron level, no significant differences could be observed between the 
different groups. 
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Fig. 16. Plasma iron levels in rabbits after oral administration of iron(II) sulfate-
containing samples 
The curves in Figure 16. reveal that the absorption was the fastest from the 
iron(II) sulfate solution administered as a control. The peak plasma iron(II) 
concentration (Cmax) (9.77 ± 3.84 pmol/L) was reached within 1 h. For the three 
formulations studied, the absorption was considerably slower: the Cmax values were 
measured 3 and 4 h after administration. The plasma level was 12.11 ± 6.43 pmol/L 
and 11.28 ± 6.16 pmol/L for sample 1 and 3, respectively. For the animals treated 
with sample 2, Cmax was only 4.90 ± 2.52 pmol/L. As regards the three preparations, 
the lowest plasma iron concentrations were measured for sample 2, and these values 
fell to the normal level by 8 h. 
The pharmacokinetic parameters determined from the curves are indicated in 
Table 9. The absorption half-life (ti/2abs) for the iron(II) sulfate solution was 0.26 h, 
whereas it was 1.66 h for sample 1, 1.07 h for sample 2 and 1.40 h for sample 3. The 
difference was significant for each formulation. Significant differences in elimination 
half-life (ti/2eiim) were observed in relation to sample 2 and 3. However, no significant 
differences were found in mean residence time (MRT) between the solution (3.92 h) 
and the samples (5.19 h, 4.05 h and 5.06 h, for samples 1-3, respectively). The time to 
peak plasma concentration (tmax) was 1.07 h for the solution, in contrast with 3.06 h 
for sample 1, 2.58 h for sample 2 and 3.03 h for sample 3. The differences were 
significant. 
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The highest Cmax was measured for sample 1 and 3 (13.88 and 12.41 pmol/L, 
respectively), followed by the aqueous solution (9.65 pmol/L) and sample 2 (5.58 
pmol/L). The AUC values extrapolated to infinity were higher for sample 1 and 3 
(95.6 pmol/L-h and 68.7 pmol/L-h) than for the solution (46.4 pmol/L-h), but the 
difference was significant only in the case of sample 1. The bioavailability relative to 
the iron(II) sulfate solution was 205.9%, 147.9% and 47.5% for sample 1, 3 and 2, 
respectively. 
Table 9. Pharmacokinetic parameters calculated from plasma curves of rabbits after oral 
administration of iron(II) sulfate-containing samples 
Treatment Absorption 
half-life (h) 
Elimination 
half-life (h) 
MRT 
(h) 
tmax 
(h) 
r 
T-max 
(pmol/l) 
AUCoo 
(pmol/l*h) 
Bioavailability* 
(%) 
Solution 0.26 2.38 3.92 1.07 9.65 46.4 100.0 
(n=6) ±0.10 ±0.46 ± 1.25 ±0.22 ±3.60 ±34.4 
Sample 1 1.66** 1.84 5.19 3.06** 13.88 95.6** 205.9 
(n=6) ±0.77 ±0.85 ±2.21 ± 1.27 ±6.09 ±57.7 ± 113.5 
Sample 2 1.07** 1.42** 4.05 2.58** 5.58 22.1 47.5 
(n=6) ±0.52 ±0.46 ±0.62 ±0.84 ±2.33 ±6.41 ± 12.6 
Sample 3 1.40** 1.60** 5.06 3.03** 12.41 68.7 147.9 
(n=6) ±0.34 ±0.23 ±0.97 ±0.31 ±8.18 ±34.5 ±67.9 
""bioavailability relative to solution (100%), 
**mean difference related to solution is significant (p<0.05) 
The results of the in vivo experiments indicate that all three formulations 
belong to the sustained-release category. The absorption half-lives of the products 
were significantly increased relative to that of the iron(II) sulfate solution, and the 
active agent reached the Cmax statistically later for all three preparations. The highest 
Cmaxand AUC values were measured for the product produced with stearin (sample 1) 
and that containing stearin (sample 3). The kinetic parameters revealed that the best 
sustained-release preparation was the product which contained stearin as bed material. 
The sustained release of the active agent led us to expect that the effect would 
be achieved without accompanying gastric irritation. To check on this, the gastric 
mucosa of the rabbits was examined after the in vivo study. After treatment with the 
iron(II) sulfate solution, considerable gastric irritation was observed (Fig. 17.) as a 
result of the iron reaching the stomach suddenly in a high concentration. However, no 
gastric irritation was noticed after the in vivo treatment of the three samples (Fig. 18.). 
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Fig. 17. Gastric mucosa after treatment with 
iron(II) sulfate solution 
Fig. 18. Gastric mucosa after treatment with 
sustained release preparation (sample 3) 
In vitro/in vivo correlation 
The in vitro/in vivo correlations for the three formulations were explored by 
comparing the in vivo drug release obtained from deconvolution with the in vitro 
release data [125]. The results in Figure 19. indicate approximately linear correlations 
between the in vivo and the in vitro fractional release for the matrix systems. The 
slopes and the intercepts obtained from the pooled data for the three formulations 
suggested that the overall in vitro release is faster than the in vivo release. 
Sample 1: 
y = 1 .7879X + 0 . 0 7 3 5 
R 2 = 0 . 9 6 8 7 
Sample 2: 
y = 4 . 2 4 8 4 X + 0 . 0 2 7 6 
R 2 = 0 . 9 7 5 
Sample 3: 
y = 3.3584X - 0.0207 
R2 = 0.9624 
Fig. 19. In vitro/in vivo correlation based on pooled data of samples produced with special 
hot melt technology 
Morphological analysis 
These investigations related in part to the properties of the particles (before 
and after administration) and in part to the potential irritation of the gastric mucous of 
the rabbits. 
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The electron microscopic pictures showed that each particle has a spherical 
form with a more or less even and continuous surface. The quality of the surface was 
crucially determined by the bed materials. 
Sample 1, prepared with stearin (Fig. 20.), has an uneven surface with cracks 
in it (Fig. 20a). The iron liberation is presumed to be accelerated by dissolution 
through these cracks. After the animal tests, the particles in the stomach of the 
animals were found to be unbroken, i.e. the particles did not disintegrate in vivo. The 
auxiliary agent remained as a framework keeping the spherical shape, but superficial 
changes were noted. The surface became even, the cracks disappeared (Fig. 20b) and 
recrystallization of the stearin could be observed (Fig. 20c). 
a b c 
Fig. 20.: Electron microscopic pictures of sample 1 (bed material: stearin): surface of the 
intact particle (a), surface of the particles after the in vivo study (b, c) 
For sample 2, prepared with white wax (Fig. 21.), the particle surface was 
completely smooth, and no cracks were noted (Fig. 21a). Sample 2 had a more 
compact structure than that of sample 1. The particles remained unbroken after the in 
vivo study, but traces of superficial erosion (Fig. 21 b) and iron(II) sulfate aggregation 
on the surface (Fig. 21c) could be observed. 
a b c 
Fig. 21.: Electron microscopic pictures of sample 2 (bed material: white wax): surface of the 
intact particle (a), surface of the particles after the in vivo study (b, c) 
x 2 0 0 7 9 8 6 B . B k V ZBBum 
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Sample 3, which contained both of the bed materials, also had a smooth, even 
surface (Fig. 22.). The explanation of this even surface is that a mixture of stearin and 
white wax in a ratio of 1:1 was used and the white wax corrected the roughness of the 
surface (Fig. 22a). After the animal tests, the particles found in the stomach of the 
animals had a spherical shape, but the surface had become uneven as a result of the 
dissolution of iron(II) sulfate (Fig. 22b). After the in vivo study, the particles exhibited 
a spongy structure (Fig. 22c). 
a b c 
Fig. 22.: Electron microscopic pictures of sample 3 (bed material: stearin and white wax): 
surface of the intact particle (a), surface of the particle after the in vivo study (b), cross-section 
of the particle after the in vivo study (c) 
The samples were submitted to the X-ray powder diffraction assay to establish 
the effect of the heat-treatment related to the special hot melt technology in the 
structure of the bed materials. The test shows that no structural change occurred in the 
stearin and white wax during the processing. 
5.2.2 Use of semisynthetic bed materials (glycerine derivatives) in the melt 
technology 
Iron(II) sulfate containing solid matrices were developed with special hot melt 
technology also with the use of new and modern auxiliary materials such as glycerine 
derivatives. The bed materials were Compritol ATO 888® (glyceryl-behenate) and 
Precirol ATO 5® (glyceryl-palmitostearate). 
Pharmaceutical technological evaluation of samples 
The melt technology resulted in round particles again. Two new samples 
signed as sample 4 (Compritol ATO 888®) and sample 5 (Precirol ATO 5®) were 
produced with glycerine derivatives. The results of the pharmaceutical technological 
evaluation of the samples are presented in Table 10. 
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Table 10. Parameters of iron(II) sulfate monohydrate containing samples produced with 
glycerine derivatives as bed material(the composition is shown in Table 6.) 
Sample 4 Sample 5 
Particle mass (mg) 13.18 
±0.003 
12.74 
± 0.003 
Particle size (mm) 2.2 ± 0.227 
2.1 
±0.121 
Particle's total Fe(II)S04*H20-content 
(mg) 
5.08 
±0.128 
5.49 
±0.082 
Particle's Fe3+ content (%)* 
•starting Fe3+ content: 0.40% 
0.42 
± 0.020 
0.43 
± 0.020 
The mean mass of the particles is almost the same in the new products. In 
comparison with the other samples (sample 1-3), the particle sizes of sample 4 and 5 
are greater. The mean particle mass is about 13 mg and their diameter is more than 2 
mm. 
The particles contain an average amount of 5 mg iron(II) sulfate monohydrate. 
This iron content is lower than the content of samples 1-3. The difference between the 
mass, size and iron content can be explained by the different drop forming properties 
and viscosity and by the different density of glycerine derivatives and the natural bed 
materials, such stearin and white wax. Oxidation was also low during the production, 
Q I 
it was not more than 0.02-0.03% in comparison with the initial Fe -amount. The low 
standard deviations support the reproducibility of production with this technology. 
In vitro drug release study 
The glycerine derivatives slowed the drug release in the in vitro drug release 
test (Fig. 23.). The rates of dissolution were different but fundamentally low in both 
cases. A greater quantity of iron(II) sulfate was dissolved from sample 4 (which 
contained Compritol ATO 888 " as bed material), 45% of the total iron content was 
liberated. This liberation was the same as the drug liberation from sample 3, which 
disposed the best in vitro and in vivo properties in the first part of our investigation. 
From sample 5, 22% of the total drug content was liberated during the study. This is 
similar to the drug liberation from sample 2, which contains only white wax and 
showed the worst properties. However, the standard deviations were lower, and this 
indicates more uniform iron release from sample 4 and 5. 
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* 1 1 1 1 1 
0 1 2 3 4 5 6 
Time (h) 
Fig. 23. In vitro dissolution of iron(II) sulfate in artificial gastric fluid at 37 °C, from samples 
4 and 5 
The kinetic calculation demonstrated that the release of iron(II) sulfate from 
sample 4 occurred according to zero order kinetics. The calculated rate constants and 
correlation coefficients are shown in the Table 11. On the basis of these values, drug 
liberation from sample 5 cannot be described either as zero or as first order kinetics. 
Table 11. Kinetic parameters of samples (based on in vitro experiment) 
zero-order model first-order model 
rate constant 
(k) 
correlation 
coefficient 
(R) 
rate constant 
(k) 
correlation 
coefficient 
(.R) 
Sample 4 -6.8263 0.9770 -0.0401 0.9874 
Sample 5 -3.1372 0.8760 -0.0159 0.8942 
The results of pharmaceutical technological evaluation, the in vitro drug 
release test and the kinetic calculations confirm that glycerine derivatives are 
applicable in the melt technology as new and modern bed materials and are able to 
produce a solid dosage form with slow drug release. There were no in vivo tests with 
sample 4 and 5. 
Morphological investigations were also performed. The stereo microscopic 
picture of sample 4 (Fig. 24a) shows homogeneous particle size distribution and 
round particle shape. The surface is even and smooth. The electron microscopic 
pictures reveal a continuous surface (Fig. 24b) composed by Compritol ATO 888®, 
which is a bit puckered (Fig. 24c). 
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a b c 
Fig. 24. : Stereo microscopic (a) and electron microscopic (b, c) pictures of sample 4 which 
contains iron(II) sulfate and Compritol ATO 888® 
The stereo microscopic picture of sample 5 (Fig. 25a) produced with Precirol 
ATO 5® also shows round particles with homogeneous particle size. A more and less 
even surface (Fig. 25b) can be seen in the electron microscopic pictures, but this 
surface is not continuous, crystals can be observed (Fig. 25c). 
a b c 
Fig. 25. Stereo microscopic (a) and electron microscopic (b, c) pictures of sample 5 which 
contains iron(II) sulfate and Precirol ATO 5® 
The effect of heating during the process of special hot melt technology in the 
structure of auxiliary materials was checked with X-Ray powder diffraction assay. 
The analysis of Compritol ATO 888® showed two characteristic peaks with different 
intensity (Table 12). The repeated test after the hot melt process shows a decrease of 
15% in the crystalline phase, which indicates structural realignment upon the effect of 
heating accompanying the process. The X-ray powder diffractogram of Precirol ATO 
(R) 
5 shows 4 typical peaks, two of which occur at the 2 0 value characteristic of 
(R) 
Compritol ATO 888 . The counts's number related to the angles of incidence clearly 
indicates that heating effects a greater change in the structure and in the crystalline-
amorphous ratio in Precirol ATO 5® than in Compritol ATO 888®. This change can 
probably be related with the difference observed in the in vitro drug release. 
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Table 12. The crystalline and the amorphous rate in glycerine derivatives 
Compritol ATO 888®- before heating Compritol ATO 888*-after heating Change** 
(%) 2 © |°| 21.090 23.095 21.080 23.025 
Crystalline 
part 
[cps]* 
63152 16615 55131 13619 -15.37 
Amorphous 
part 
[cps] 
6889 6273 5806 6593 -10.62 
Precirol ATO 5®-before heating Precirol ATO 5®-after heating 
2© |°| 5.355 19.370 21.105 22.820 5.280 19.385 21.165 23.170 
Crystalline 
part 
[cps] 
4984 22530 23409 23470 4570 13502 30102 17450 -11.36 
Amorphous 
part 
[cps] 
1584 3249 3540 3832 1616 4844 4858 4886 +28.96 
*cps= counts per secundum 
** mean change, calculated from cps related to the 2© values 
5.2.3 Conclusion 
The results confirm the applicability of the special hot melt technology in the 
production of iron(II) sulfate-containing drop-formed particles with round shape. The 
processing of iron is achievable successfully using lipophilic skeleton-building 
materials with a low melting temperature. The conventional natural materials (stearin 
and white wax) and the new auxiliary materials of pharmaceutical technology 
(Compritol ATO 888®, Precirol ATO 5®) are also applicable. The production of 
samples with special hot melt technology is well reproducible, quick and cost-saving. 
Iron is not oxidized notably during the process. 
The conventional natural materials ensure the iron release from samples 
according to zero order kinetics. The in vivo experimental results in rabbits correlate 
well with the results of the in vitro tests. The samples have good bioavailability. 
The investigations with glycerine derivatives confirm the applicability of such 
materials in modern iron-processing. They slow down iron release, and the liberation 
of the active agent can be regulated by using their sufficient amount and with the 
addition of other materials. The bed materials form a matrix in the products, protect 
the iron from oxidation and ensure slow drug release. 
It can be stated that drop solidification from the melt is suitable to produce a 
solid product with sustained drug release. The regulation of drug release in this 
manner can be advantageous especially in the case of gastric-irritating active agents 
like iron(II) sulfate. 
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5.3 Results 2-Experimental results of iron(II) sulfate samples produced with 
spherical crystallization 
Crystallization from solution is a possibility to produce iron(II) sulfate crystals 
which are suitable for formulating a new solid dosage form. The spherical crystals 
produced in this way have several advantages, which facilitate further production 
steps (e.g. coating) and the formation of the final dosage form. 
Results of the preformulation studies 
Different samples were produced during the preformulation studies and were 
examined parallelly. 11 crystallized samples (signed as Fe/2 - Fe/11) were produced 
by changing the process parameters (Table 13.). The production and the testing were 
performed in two parts. 
Table 13. Crystallization parameters of iron(ll) samples (Fe/2-Fe/l 1) in preformulation 
studies 
Sample Ts 
(°C) 
V c 
(°C/min) 
Cooling 
method 
n 
(min1) 
Solvent Ms 
(g) 
Fe/2 54 0.35 lin. 600 tap water 6 
Fi
rs
t p
ar
t 
Fe/3 54 1.3 lin. 600 tap water 0 
Fi
rs
t p
ar
t Fe/4 58 varying exp. 600 tap water 0 
Fi
rs
t p
ar
t 
Fe/5 58 varying exp. 600 distilled 
water 
0 
Fi
rs
t p
ar
t 
Fe/6 58 0.33 lin. 800 distilled 
water 
0 Fi
rs
t p
ar
t 
Fe/7 58 0.33 lin. 800 distilled 
water 
0 
Fi
rs
t p
ar
t 
Fe/8 58 10.55 lin. 800 deionized 
water 
0 
Se
co
nd
 p
ar
t 
20.2 
Se
co
nd
 p
ar
t 
Fe/10 58 0.28 lin. 800 deionized 
water 
0 
Se
co
nd
 p
ar
t 
*Fe/l 1 58 0.17 lin 800 deionized 
water 
0 S
ec
on
d 
pa
rt
 
Ts= starting temperature, Vc= cooling rate, n= agitation speed, Ms= seed crystal 
' between 0 and 60. min. 
2 between 60. and 135. min. 
• + 1 hour mixing after the end of crystallization (15 °C) 
The particle size distribution, the time of flow (flowability), the bulk density 
and the roundness of the crystallized samples were tested. From the economic point of 
view, a requirement of the produced crystals is that the size of most of the particles 
should be between 0.5 and 1.0 mm because these crystals can be used for coating. 
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In the first part of the preliminary study (Table 13.) those experiments gave 
the best result in which a starting temperature of 58 °C, a linear cooling method, an 
agitation speed of 800 1/min and no seeding were applied. Using these parameters in 
the second part, the effect of cooling rate was examined and deionized water was used 
to avoid the effect of solvent ions. The ions can disturb nucleation and crystal growth, 
and thus the reproducibility of crystal production. The parameters of crystallized 
products in the second part are presented in Tables 14. and 15. 
Table 14. Particle size distribution of iron(II) sulfate samples (Fe/8-Fe/l 1) produced with 
spherical crystallization in the second part of preliminary studies 
Sample > 1.0 1.0-0.8 0.8-0.71 0.71-0.5 0.5-0.4 <0 .4 
mm mm mm mm mm mm 
Fe/8 (g) 0.1 0.1 3.6 34.0 19.4 42.8 
Fe/10 (g) 1.3 12.2 11.5 41.1 15.7 18.2 
Fe/11 (g) 38.3 18.6 9.4 23.6 5.9 4.2 
Table 15. Time of flow, bulk density and roundness of the crystallized products 
Sample Time of flow 
(s/100 cm3) 
Bulk density 
(g/cm3) ' Roundness 
Fe/8 8 0.943 1 .4610.26 
Fe/10 8 0.971 1 .3210.12 
Fe/11 10 1.010 1 .2110.09 
There are no significant differences in the samples with respect to their bulk 
density and roundness. Their flowability was proper based on the time of flow. 
Sample Fe/10 was the best as concerns particle size distribution, but the best values 
for roundness, standard deviation of roundness and bulk density were given by sample 
Fe/11 produced with the smallest cooling rate. 
The crystal-water content of the produced samples was tested with 
thermoanalytical examinations and it was calculated from the decrease of sample 
mass. The water content determined was the following: Fe/8: 6.27 mol, Fe/10: 6.88 
mol, Fe/11:6.70 mol H 2 0. 
Results of the scale up process 
A fivefold scaled up experiment was executed by applying parameters found 
to be the best in laboratory (Fe/11) experiments. The recrystallization was performed 
in deionized water with no addition of seed crystals and by cooling in a linear manner, 
with 0.2 °C/min cooling rate. Agitation rate was adapted to the larger scale in order to 
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yield similar mixing to the lab experiment: it was decreased from 800 to 400 min 
The composition of solution was: 1.81 kg FeSOWH^O and 1.35 kg deionized water. 
The particle size distribution of crystals produced in the best laboratory experiment 
(Fe/11) and the scaled up crystallization (Fe/12) is compared in Figure 26. 
Fe/11 
I Fe/12 
> 1 mm 1-0.5 mm < 0.5 mm 
particle size (mm) 
Fig. 26. Particle size distribution of samples Fe/11 and Fe/12 
Data in Figure 26. show that scale up effected an improvement in the particle 
size distribution. The rate of samples in the range of 0.5 - 1 mm increased, more than 
60% of Fe/12 belongs to this range. Thus the scale up process was expressly 
favourable with respect to particle size. The other characteristics (mean diameter, time 
of flow, bulk density, roundness) of Fe/12 in comparison with Fe/11 are shown in 
Table 16. 
Table 16. The comparison of the pharmaceutical technological parameters of samples Fe/11 
and Fe/12 
Sample Mean diameter (pm) 
Time of flow 
(s/100 cm3) 
Bulk density 
(g/cm3) * Roundness 
Fe/11 734±183 10 1.010 1.21 ±0.09 
Fe/12 729 ± 165 8 0.994 1.32 ±0.11 
The flowability of sample Fe/12 did not change greatly, the bulk density 
decreased slightly and the roundness became slightly worse but it was still 
satisfactory. However, these changes are not significant and sample Fe/12 was given 
good classification. 
Morphological analysis 
The images of the iron(II) sulfate heptahydrate available in trade and 
developed by means of spherical crystallization are demonstrated by stereo 
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microscopic pictures. The iron(II) sulfate available on the market (Ph. Hg. VII.) is 
greatly heterogeneous, the crystal shape is diverse (Fig. 27.). As concerns the crystal 
habit, crystals are mainly monoclinic but orthorombic crystals can also be found, 
which is in agreement with the data in literature. The crystal surfaces are white and 
matt, which leads to the conclusion that crystal crumbling occurred due to the effect 
of the atmosphere. 
a. (size range: 10 pm-2 mm) b. (size range: 0,5-1,0 mm) 
Fig. 27. Stereo microscopic pictures of iron(II) sulfate heptahydrate crystals available in trade 
(a) and developed (b) 
The crystals of sample Fe/12 developed by spherical crystallization from 
solution are like glass, semitransparent with sea-green colour and their shape is 
approximately round. The conventional BCC-cubic structure of crystals is 
transformed into a rounded, spherical form owing to the parameters of the 
crystallization process. 
Crystal-coating process 
The aim was partly to prove that the spherical crystals can be coated fast and 
easily, and partly to form a coat on the particles which can control the release of 
iron(II) sulfate. The starting material was 100 g from the 0.5-1 mm fraction of sample 
Fe/12. The coating experiments were performed in all three cases in a steel pan with 
the spraying method in such a way that the same amount of iron(II) sulfate was 
treated with various amounts of stearin. Spraying was carried out with a solution of 
stearin in 95% ethyl alcohol having a temperature of 60 °C. The composition of the 
coated products (HPT-1, HPT-2, HPT-3) is shown in Table 17. 
f V 
I • • • > 
Table 17. The composition of the coated samples. 
HPT-1 HPT-2 HPT-3 
Amount of FeS04*7 H 2 0 (g) 100 100 100 
Composition 
of the final 
product*: 
Iron(II) sulfate heptahydrate (%) 95.5 89 72 
Amount of stearin (%) 4.5 11 28 
* The determination of iron was performed by atomic absorption method at 248.3 nm in air-acetylene 
gas after a bunting process (500 °C, 24 h). 
The difference between the samples concerning the quantity of iron(II) sulfate 
heptahydrate and stearin is illustrated clearly by the data in Table 17. 
Investigation of coated samples 
The particle size distribution of coated samples (HPT-1, HPT-2, HPT-3) is 
demonstrated in Figure 28. It is obvious that the particle size distribution of the coated 
products changes parallelly with the increase in the quantity of stearin. With 
increasing amounts of stearin, the ratio of particles larger than 1 mm increased, while 
the ratio of particles belonging to the 0.5-1 mm range and smaller than 0.5 mm 
decreased. 
HPT-1 HPT-2 HPT-3 
Samples 
Fig. 28. Particle size distribution of coated iron(II) sulfate heptahydrate samples 
The roundness and diameter values of both the starting and the coated particles 
are shown in Table 18. The data in Table 18. correlate well with the data of Figure 28. 
in the sense that the mean diameter of samples increased proportionally with the 
amount of stearin. The roundness values were also changed but improvement was 
found only in the case of samples HPT-1 and HPT-3, and the 11% of stearin used as 
coating material in sample HPT-2 did not modify the roundness of the starting 
material. 
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Table 18. Parameters of the starting and the coated particles 
Starting 
FeS04*H20 
HPT-1 HPT-2 HPT-3 
Roundness (Leica) 1,32 ±0,11 1,27 ±0,11 1,32 ±0,08 1,19 ±0,05 
Diameter (Leica) (pm) 729 ± 165 768 ± 173 782 ±172 894 ± 152 
In vitro drug release study 
The rate of dissolution of the active agent from coated products in artificial 
gastric juice is illustrated in Figure 29. The values are expressed in the amount of 
iron(II) sulfate heptahydrate and are related to the maximum releasable active agent 
content in percentage. 
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Fig. 29. In vitro drug release of coated samples in artificial gastric juice 
The liberation of the active agent from samples coated with different amounts 
of stearin was found to be significantly different. The total iron content was liberated 
from the sample HPT-1 during the first 0.5 hour of study. It can be seen in the 
diagram that the values measured at the beginning of the study exceeded 100 %. The 
value of 107.5% and the high standard deviation which appeared at the 0.5 hour 
indicate the insufficient mixing of the system. The solution was not homogeneous 
after 30 minute. This is also supported by the fact that the amount of released iron(II) 
sulfate became "steady" around 100% in time, and at the same time the standard 
deviation values decreased. This indicates that the system became homogeneous at the 
end of the dissolution test. The drug release from sample HPT-2 was uniform, in the 
0.5 hour 28.8 % of the active agent was detected and 72.6 % of the total drug content 
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was liberated during the study. From sample HPT-3 the whole liberation was only 
6%. Kinetic calculations were also performed on the basis of the results of the in vitro 
dissolution test (Table 19.). 
Table 19. Kinetic parameters of coated iron(II) sulfate heptahydrate samples 
zero-order model first-order model 
rate constant 
(k) 
correlation 
coefficient 
(R) 
rate constant 
(k) 
correlation 
coefficient 
(R) 
HPT-1 - - - -
HPT-2 -15.717 0.9085 -0.130 0.9481 
HPT-3 -1.161 0.9124 -0.005 0.9189 
Sample HPT-1 cannot be described either as zero or as first order kinetics 
because of the fast drug liberation. The correlation coefficients of HPT-2 and HPT-3 
calculated according to the two kinetic models are similar. The rate constant 
belonging to HPT-2 considering the rise of the curve indicates a value similar to that 
of Sample 1, produced with special hot melt technology. In view of this, sample HPT-
2 can be expected to have the best bioavailability. 
Morphological investigation 
Stereo microscopic pictures are shown in Figure 30. Sample HPT-1 has a 
favourable roundness compared to the roundness of the uncoated crystals. Stearin, 
used in as small an amount as 4.5%, levels off the unevenness of particles by sticking 
to surface holes but this amount is not sufficient to form an even, properly thick layer 
on the surface of crystals. As a consequence, release of the active agent from the 
sample is too fast. The roundness of sample HPT-2 is equal to the roundness of the 
uncoated crystals. In this sample stearin, which was applied in 11% compared to 
iron(II) sulfate, covers the entire surface of particles with an evenly thick layer and 
does not change the shape and roundness of crystals. So the rate of dissolution of iron 
measured in vitro shows slow, properly sustained release. The roundness of crystals is 
improved (even better than the roundness of sample HPT-1), which can be attributed 
to the 28% of stearin used. The thick layer not only smoothes the surface of crystals 
but retards release of iron(II) sulfate exaggeratedly under in vitro circumstances. 
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HPT-1 HPT-2 HPT-3 
(mean diameter:768 pm) (mean diameter:782 gm) (mean diameter:894 gm) 
Fig. 30. Stereo microscopic pictures of iron(II) sulfate heptahydrate crystals coated with 
stearin 
5.3.1 Conclusion 
The following statements can be made in connection with the spherical 
crystallization of iron(II) sulfate heptahydrate and the coating of developed crystals: 
With the use of non typical spherical crystallization in lab experiments, spherical 
iron(II) sulfate heptahydrate crystals were developed with a mean diameter of 0.5-1 
mm. The procedure is simple, fast and does not require a dangerous, expensive 
solvent. In a fivefold scaled up experiment the desired requirements of particles were 
achieved. The size and the surface of the spherical crystals were suitable for coating. 
The coating procedure was developed for coating the surface of particles prepared by 
crystallization. The rate of iron(II) sulfate release was influenced by the thickness of 
the stearin layer. As a result of our development, the filling of spherical crystals into 
capsules to form the final dosage form can be proposed. 
6. Summary 
The aim of my PhD work was to prepare a solid dosage form from different 
hydrate forms of iron(II) sulfate using the melt solidification in drops method (special 
hot melt technology) and the non typical spherical crystallization process. These are 
new technologies in the field of pharmaceutical technology and have not been used 
before. 
I acquired the technology of melt solidification in drops in Germany, in the 
Institute of Process Engineering of Martin Luther University, Halle-Wittenberg. After 
the preformulation studies (contact angle measurement, determination of surface free 
energy etc.) this method is suitable for the fast and simple preparation of the solid 
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product in one production step. The produced particles are round with a definite 
particle size. 
Another advantage is that the liberation of the active agent is regulated at the 
same time, but it can be used only in the case of thermorésistant drugs. The first 
finding in the course of my investigations was that iron(II) sulfate monohydrate is 
suitable for the special hot melt technology because of its greater resistance during the 
heating process. 
The spherical crystallization of iron(II) sulfate was attained with the help of 
crystallizer specialists of EGIS pharmaceutical company. Iron(II) sulfate can be 
crystallized from solution in a heptahydrate form. This method is applicable well if 
the aim is to give shape and to change the crystal habit already in the course of raw 
material manufacturing. After the establishment of the adequate parameters of the 
crystallization process, crystals with a defined particle size can be produced. 
The results of my investigations concerning the working-out of both 
technologies are the following: 
=> I found that the results of the samples developed by special hot melt 
technology confirm the applicability of this method in iron processing. The 
production of iron-containing solid particles is fast, simple and well reproducible. 
Natural auxiliary materials such as stearin and white wax are well applicable in the 
production, they protect the active agent and ensure slow drug liberation. The slow 
drug release means prolonged drug effect and uniform drug plasma concentration in 
the body together with the decrease of the risk of gastric mucosa irritation. The 
oxidation of iron was reduced, the increasing of the Fe3+content in samples was 
minimal compared to the starting material. 
=> Moreover, I found that spherical iron(II) sulfate heptahydrate crystals can 
be crystallized from solution with the use of the non typical spherical crystallization 
process. The production of spherical crystals is simple and fast if the parameters of 
crystallization are optimized. I developed the crystal coating process. The produced 
coat from stearin protects the iron from oxidation and inhibits the loss of crystal 
water. Drug liberation can be prolonged through the coat. 
The production of solid dosage form (tablet, capsule) from iron compounds 
with conventional present-day technologies is difficult and circuitous. Production 
consists of several production steps, all of which are expensive and require a long 
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time. With the use of the special hot melt technology and the non typical spherical 
crystallization process, a solid dosage form suitable for direct peroral administration 
can be produced from iron(II) sulfate in a fast and simple manner (Fig. 31.). 
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Fig. 31. The routine of iron processing with conventional and new methods 
On the basis of my investigations both the special hot melt technology and the 
non typical spherical crystallization process are suitable for the production of solid 
dosage forms from iron(II) sulfate. The technological course of processing is 
shortened by these methods. The filling of round particles is suggested first of all into 
capsules, thereby forming a modern and popular final dosage form. 
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